Retrospective Study
Copyright ©The Author(s) 2018.
World J Hepatol. Jan 27, 2018; 10(1): 82-87
Published online Jan 27, 2018. doi: 10.4254/wjh.v10.i1.82
Table 1 Univariate analysis of factors in non-liver cirrhosis and liver cirrhosis groups
Non-LC group, n = 202LC group, n = 100P-value
Etiology
HBV43 (21.2%)10 (10.0%)
HCV89 (44.1%)72 (72.0%)
NBNC70 (34.7%)18 (18.0%)< 0.001
Edmonson-Steiner grade
I30 (30.0%)36 (17.8%)0.07
II64 (64.0%)151 (74.8%)
III4 (4.0%)13 (6.4%)
IV2 (2.0%)2 (1.0%)
PLT, × 104/μL18.9 ± 8.111.6 ± 4.6< 0.0001
MPV, fL10.2 ± 0.910.8 ± 0.9< 0.0001
MPV/PLT ratio0.64 ± 0.301.10 ± 0.51< 0.0001
PT, %92.9 ± 11.782.5 ± 11.1< 0.0001
AST, IU/L42 ± 2651 ± 23< 0.0001
ALT, IU/L40 ± 3047 ± 330.02
Total-bilirubin, mg/dL0.67 ± 0.230.90 ± 0.34< 0.0001
Albumin, g/dL3.8 ± 0.53.6 ± 0.40.01
Cholinesterase, IU/L235 ± 80193 ± 60< 0.0001
Type 4 collagen, ng/mL6.3 ± 2.49.1 ± 4.40.04
Hyaluronic acid, ng/mL147 ± 179312 ± 318< 0.0001
ICGR15, %14.1 ± 8.322.1 ± 12.1< 0.0001
GSA Rmax, mg/min0.62 ± 0.210.44 ± 0.17< 0.0001
Table 2 Multivariate analysis of factors predicting liver cirrhosis
Odds ratioP-value95%CI
MPV/PLT ratio≥ 0.71, n = 1513.71< 0.00011.94-7.28
< 0.71, n = 151
PT, %≥ 89.0, n = 1512.680.00181.44-5.06
< 89.0, n = 151
AST, IU/L≥ 39, n = 1553.300.011.30-9.09
< 39, n = 147
ALT, IU/L≥ 34, n = 1532.570.041.02-7.09
< 34, n = 149
Total-bilirubin, mg/dL≥ 0.7, n = 1771.890.041.00-3.61
< 0.7, n = 125
Albumin, g/dL≥ 3.8, n = 1680.950.890.47-1.89
< 3.8, n = 134
Cholinesterase, IU/L≥ 211, n = 1520.980.960.48-1.98
< 211, n = 150
Type 4 collagen, ng/mL≥ 6.5, n = 1660.950.860.51-1.72
< 6.5, n = 136
Hyaluronic acid, ng/mL≥ 124, n = 1532.280.0081.23-4.26
< 124, n = 149
ICGR15, %≥ 14.3, n = 1511.400.300.72-2.68
< 14.3, n = 151
GSA Rmax, mg/min≥ 0.555, n = 1511.510.240.75-3.04
< 0.555, n = 151